Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Algen Biotechnologies
AddedMar 22, 2024
UpdatedJul 2, 2026
Algen Biotechnologies

Algen Biotechnologies

Seed

Decoding gene networks for therapy.

HQ
San Francisco, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize therapeutic discovery, Algen Biotechnologies focuses on decoding functional gene networks to advance medical treatments. The company leverages cutting-edge biotechnology to build platforms that unravel the complexities of gene interactions, aiming to identify novel therapeutic targets. Their core vision is to transform healthcare by providing innovative solutions that address unmet medical needs, particularly in the realm of genetic diseases and personalized medicine.

Algen Biotechnologies has attracted notable investors and industry experts who recognize the potential of their groundbreaking work. The company has achieved significant milestones in developing its proprietary platform, which has garnered attention for its potential to accelerate drug discovery and development. Through strategic partnerships and a dedicated team of scientists, Algen Biotechnologies continues to make impactful contributions to the biotech industry, positioning itself as a leader in the field of therapeutic discovery.

Algen Biotechnologies - Similar Companies

BridGene Biosciences logo

BridGene Biosciences

Fauna Bio logo

Fauna Bio

faunabio.com

Alltrna logo

Alltrna

alltrna.com

Alphina Therapeutics logo

Alphina Therapeutics

Anagenex logo

Anagenex

anagenex.com

TigerGene logo

TigerGene

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

GEn1E Lifesciences logo

GEn1E Lifesciences

gen1e.com

Epic-Bio logo

Epic-Bio

epic-bio.com

Aureka Biotechnologies logo

Aureka Biotechnologies

aurekabio.com

Locanabio logo

Locanabio

Excepgen logo

Excepgen

excepgen.com

Alga Biosciences logo

Alga Biosciences

alga.bio

Selonterra logo

Selonterra

selonterra.com

Rezo Therapeutics logo

Rezo Therapeutics

rezotx.com

Algen Biotechnologies - Quick Facts

Who are Algen Biotechnologies' competitors?

Companies similar to Algen Biotechnologies include BridGene Biosciences, Fauna Bio, Alltrna and Alphina Therapeutics.

When was Algen Biotechnologies founded?

Algen Biotechnologies was founded in 2018.

Where is Algen Biotechnologies' headquarters located?

Algen Biotechnologies' headquarters is located in San Francisco, CA, US.

When was Algen Biotechnologies' last funding round?

Algen Biotechnologies' most recent funding round was for $150k (USD) in August 2021.

How much has Algen Biotechnologies raised to-date?

As of Aug 19, 2021, Algen Biotechnologies has raised a total of $150k (USD).

How many employees does Algen Biotechnologies have?

Algen Biotechnologies has 7 employees as of Feb 24, 2024.

Algen Biotechnologies - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Discovery
  • Therapeutics
Tags
  • GenAI
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software